Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Комбинация амлодипина и аторвастатина – удачный дуэт в лечении больных с метаболическим синдромом
Комбинация амлодипина и аторвастатина – удачный дуэт в лечении больных с метаболическим синдромом
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Успех в лечении и снижении риска развития атеросклероза и сердечно-сосудистых осложнений у больных с метаболическим синдромом (МС) может быть реализован не только при адекватном контроле артериального давления, но и компенсации метаболических нарушений, в частности дислипидемии, которая встречается у большинства больных с МС. Назначение сочетанной терапии блокаторов кальциевых каналов и статинов может стать приоритетным у данной категории больных.
Ключевые слова: метаболический синдром, артериальная гипертония, амлодипин, аторвастатин.
Key words: metabolic syndrome, arterial hypertension, amlodipine, atorvastatin.
Ключевые слова: метаболический синдром, артериальная гипертония, амлодипин, аторвастатин.
________________________________________________
Key words: metabolic syndrome, arterial hypertension, amlodipine, atorvastatin.
Полный текст
Список литературы
1. McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385–90.
2. Sidorenkov O, Nilssen O, Brenn T, Martiushov S, Arkhipovsky VL, Grjibovski AM. Prevalence of the metabolic syndrome and its components in Northwest Russia: The Arkhangelsk study. BMC Public Health 2010; 19: 10–23.
3. The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association. Circulation 1999; 100: 1132–3.
4. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–14.
5. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
6. Жернакова Ю.В., Чазова И.Е., Мычка В.Б., Олимпиева С.П. Тяжесть метаболического синдрома определяется числом его компонентов. Системные гипертензии. 2011; 1.
7. Laakso M. Epidemiology of Diabetic Dyslipidemia. Diabetes Rev 1995; 3: 408–22.
8. Brown M, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
9. Hansson L, Hedner T, Lund-Johansen P et al. Randomised tral of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 365: 359–65.
10. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood–pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
11. Pepine CJ, Kowey PR, Kupfer S et al. INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 2006; 47: 547–51.
12. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Pressure 1996; 5: 206–8.
13. Nayler WG. Amlodipine. Berlin 1995; p. 1–273.
14. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): 1–10.
15. Burges RA, Dodd MG, Gardiner DG. Pharmacologic profile of amlodipine. Am J Cardiol 1989; 64: 101–201.
16. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004; 363 (9426): 2022–3.
17. Jukema JW, Zwinderman AH, van Boven AJ et al. The REGRESS Study Group: evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression with coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler. Thromb Vasc Biol 1996; 16: 425–30.
18. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
19. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2002; 35: 592–99.
20. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
21. Balantyne C et al. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26: 2224–31.
22. Недогода С.В. и соавт. Аторвастатин и улучшение эластичности сосудов при артериальной гипертонии. Cons. Med. 2007; 1: 12–5.
23. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
24. Golomb BA, Dimsdale JE, White HL. Reduction in Blood Pressure With Statins Results From the UCSD Statin Study, a Randomized Trial. Arch Intern Med 2008; 168 (7): 721–7.
25. Strazzullo P et al. Do statins reduce blood pressure? A meta–analysis of randomized, controlled trials. Hypertension 2007; 49: 792–8.
26. Gmerek A, Yang R, Bays H et al. Atorvastatin causes a dosedependent reduction in LDL-C and triglycerides (abstract). In 66th Congress of the European Atherosclerosis Society Abstract Book. Florence (Italy) 1996; 13 (17): 212.
27. Nawrocki JW, Weiss SR, Davidson MN et al. Reduction of LDL Cry hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscl Thromb Vasc Biol 1995; 15: 678–82.
28. Waters D. Comparison of Aggressive Lipid Lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and Conventional Care for the Reduction of Ischemic Events in Patients with Stable Coronary Artery Disease. Cardiovasc Rev Rep 2000; 21 (1): 26–31.
29. Collhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685–96.
30. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139–47.
31. Мычка В.Б., Чазова И.Е. Роль статинов в лечении больных с метаболическим синдромом. Болезни сердца и сосудов, 2007; 1: 29–32.
32. Sever PS, Dahlof B, Poulter NR, Wedel H et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
33. Messerli FH, Bakris GL, Ferrera RD et al. On behalf of the AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006; 8: 571–81.
34. Hobbs FDR, Gensini G, Mancini GBJ et al. For the JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009; 16: 472–80.
2. Sidorenkov O, Nilssen O, Brenn T, Martiushov S, Arkhipovsky VL, Grjibovski AM. Prevalence of the metabolic syndrome and its components in Northwest Russia: The Arkhangelsk study. BMC Public Health 2010; 19: 10–23.
3. The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association. Circulation 1999; 100: 1132–3.
4. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–14.
5. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
6. Жернакова Ю.В., Чазова И.Е., Мычка В.Б., Олимпиева С.П. Тяжесть метаболического синдрома определяется числом его компонентов. Системные гипертензии. 2011; 1.
7. Laakso M. Epidemiology of Diabetic Dyslipidemia. Diabetes Rev 1995; 3: 408–22.
8. Brown M, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
9. Hansson L, Hedner T, Lund-Johansen P et al. Randomised tral of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 365: 359–65.
10. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood–pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
11. Pepine CJ, Kowey PR, Kupfer S et al. INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 2006; 47: 547–51.
12. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Pressure 1996; 5: 206–8.
13. Nayler WG. Amlodipine. Berlin 1995; p. 1–273.
14. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): 1–10.
15. Burges RA, Dodd MG, Gardiner DG. Pharmacologic profile of amlodipine. Am J Cardiol 1989; 64: 101–201.
16. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004; 363 (9426): 2022–3.
17. Jukema JW, Zwinderman AH, van Boven AJ et al. The REGRESS Study Group: evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression with coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler. Thromb Vasc Biol 1996; 16: 425–30.
18. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
19. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2002; 35: 592–99.
20. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
21. Balantyne C et al. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26: 2224–31.
22. Недогода С.В. и соавт. Аторвастатин и улучшение эластичности сосудов при артериальной гипертонии. Cons. Med. 2007; 1: 12–5.
23. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
24. Golomb BA, Dimsdale JE, White HL. Reduction in Blood Pressure With Statins Results From the UCSD Statin Study, a Randomized Trial. Arch Intern Med 2008; 168 (7): 721–7.
25. Strazzullo P et al. Do statins reduce blood pressure? A meta–analysis of randomized, controlled trials. Hypertension 2007; 49: 792–8.
26. Gmerek A, Yang R, Bays H et al. Atorvastatin causes a dosedependent reduction in LDL-C and triglycerides (abstract). In 66th Congress of the European Atherosclerosis Society Abstract Book. Florence (Italy) 1996; 13 (17): 212.
27. Nawrocki JW, Weiss SR, Davidson MN et al. Reduction of LDL Cry hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscl Thromb Vasc Biol 1995; 15: 678–82.
28. Waters D. Comparison of Aggressive Lipid Lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and Conventional Care for the Reduction of Ischemic Events in Patients with Stable Coronary Artery Disease. Cardiovasc Rev Rep 2000; 21 (1): 26–31.
29. Collhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685–96.
30. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139–47.
31. Мычка В.Б., Чазова И.Е. Роль статинов в лечении больных с метаболическим синдромом. Болезни сердца и сосудов, 2007; 1: 29–32.
32. Sever PS, Dahlof B, Poulter NR, Wedel H et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
33. Messerli FH, Bakris GL, Ferrera RD et al. On behalf of the AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006; 8: 571–81.
34. Hobbs FDR, Gensini G, Mancini GBJ et al. For the JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009; 16: 472–80.
Авторы
Н.В.Блинова, И.Е.Чазова
Институт клинической кардиологии им. А.Л.Мясникова ФГУ РКНПК Минздравсоцразвития РФ, Москва
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of the Russian Federation
Институт клинической кардиологии им. А.Л.Мясникова ФГУ РКНПК Минздравсоцразвития РФ, Москва
________________________________________________
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of the Russian Federation
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.